Know the Risk of Injury and Rejection

 

MMDx uses the level of expression of selected genes or gene set measurements to assess the probability of TCMR and ABMR as well as the extent of acute and chronic injury. 

 

The report generated summarizes the key findings (e.g. inflammation, acute kidney injury and atrophy-fibrosis scores and different rejection classifier scores) as well as the overall molecular interpretation. The relationship of the new biopsy to its nearest molecular neighbors in the Reference Set estimates future graft survival. Many other classifiers are also run to establish details of ABMR.  The net result of all these measurements is integrated by a novel method called archetype analysis, a form of cluster analysis.(16)

mmdx-sample-report-kidney-page1-tn.png
Objective and Actionable Data

 

The MMDx assessment reports provides you with the following information:

Rejection related  

  • Risk of T cell-mediated rejection (TCMR)

  • Risk of Antibody-mediated rejection (ABMR)

  • Under-immunosuppression/non-adherence 

  • Objective basis for therapeutic choices

Parenchymal injury & non-rejection disease: 

  • Acute parenchymal injury 

  • Irreversible injury (atrophy scarring) 

  • Risk of progression to failure

© 2017-2019 by Thermo Fisher Scientific Inc.

  • Black LinkedIn Icon
  • Black Twitter Icon